S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

+0.05 (+2.13%)
(As of 05/17/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
208,548 shs
Average Volume
600,108 shs
Market Capitalization
$92.51 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCR2 Therapeutics logo

About TCR2 Therapeutics

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.36 per share


Net Income
$-99.81 million
Pretax Margin




Free Float
Market Cap
$92.51 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.46 out of 5 stars

Medical Sector

163rd out of 1,426 stocks

Biological Products, Except Diagnostic Industry

22nd out of 210 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics
or view top-rated stocks.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,020,000 shares, an increase of 20.2% from the April 15th total of 1,680,000 shares. Based on an average daily trading volume, of 568,300 shares, the days-to-cover ratio is presently 3.6 days. Currently, 6.9% of the company's stock are short sold.
View TCR2 Therapeutics' Short Interest

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for TCR2 Therapeutics

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its earnings results on Thursday, May, 12th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.02.
View TCR2 Therapeutics' earnings history

What price target have analysts set for TCRR?

8 analysts have issued 1 year price objectives for TCR2 Therapeutics' stock. Their forecasts range from $5.00 to $38.00. On average, they expect TCR2 Therapeutics' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 650.0% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?
TCR2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 58, Pay $916.8k)
  • Dr. Patrick A. Baeuerle Ph.D., Founder & Member of the Advisory Board (Age 64, Pay $47.02k)
  • Mr. Peter Olagunju, Chief Technical Officer (Age 44, Pay $307.42k)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 51, Pay $668.6k)
  • Carl Mauch, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel J.D., Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D., Chief People Officer (Age 48)
  • Mr. Gregg McConnell M.B.A., Head of Bus. Devel.
  • Dr. Rosemary Harrison Ph.D., Chief Bus. & Strategy Officer (Age 39)
  • Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer
What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.57%), Renaissance Technologies LLC (3.74%), Vanguard Group Inc. (2.67%), JPMorgan Chase & Co. (1.85%), State Street Corp (1.36%) and Acadian Asset Management LLC (1.24%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics

Which institutional investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., Northern Trust Corp, Harbor Capital Advisors Inc., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Oppenheimer & Co. Inc..
View insider buying and selling activity for TCR2 Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TCR2 Therapeutics stock?

TCRR stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Prudential Financial Inc., BlackRock Inc., GSA Capital Partners LLP, XTX Topco Ltd, Private Advisor Group LLC, and Nan Fung Group Holdings Ltd.
View insider buying and selling activity for TCR2 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $2.40.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $92.51 million. The company earns $-99.81 million in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 137 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 949-5200 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.